CWI1-2 is an IGF2BP2 inhibitor. CWI1-2) shows promising anti-leukemia effects in vitro and in vivo. CWI1-2 preferentially binds to IGF2BP2 and inhibits its interaction with m6A-modified target transcripts. Targeting IGF2BP2 with CWI1-2 alone, or in combination with other agents, such as daunorubicin (DNR) or homoharringtonine (HHT), shows promising therapeutic efficacy in treating AML. CWI1-2 treatment significantly delayed leukemia onset and prolonged the survival of BMT recipient mice. Importantly, monitoring of body weight from the day of drug treatment for 12-18 days did not show any reduction of body weight upon CWI1-2 treatment. CWI1-2 is an effective and largely safe leading compound targeting IGF2BP2 for AML treatment.
Cat.No
DC74824
Name
CWI1-2 HCl
Chemical Properties
CAS
2408590-37-2
Formula
C22H18CL4N6O3
MW
556.23
Storage
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
